Comments

Protagonist Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Protagonist Therapeutics (PTGX) operate in?

Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

PTGXNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$44.41

0.641.46%

At close: -

$44.41

0.000.00%

After Hours: 4:00 PM EDT

Protagonist Therapeutics (PTGX) Forecast

News Earnings Protagonist Therapeutics (PTGX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX | Benzinga

Explore Protagonist Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PTGX.

Open	$44.12
Close	$44.41
Volume / Avg.	625.80K / 1.26M
Day Range	$43.47 - $44.76
52 Wk Range	27.00 - 60.60
Market Cap	$2.75B
P/E Ratio	56.12
Dividend Yield	-
Exchange	NASDAQ
RSI	49
Short Interest	11.84%
Days to Cover	6.56

Recent News

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Vandana Singh

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Vandana Singh

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Dec 24

Feb

Mar

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$44.12
Close	$44.41
Volume / Avg.	625.80K / 1.26M
Day Range	$43.47 - $44.76
52 Wk Range	27.00 - 60.60
Market Cap	$2.75B
P/E Ratio	56.12
Dividend Yield	-
Exchange	NASDAQ
RSI	49
Short Interest	11.84%
Days to Cover	6.56

About Protagonist Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary tech...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Protagonist Therapeutics (PTGX) stock?

You can purchase shares of Protagonist Therapeutics (NASDAQ:PTGX) through any online brokerage.

View our list of the best stock brokerages

Who are Protagonist Therapeutics (PTGX) competitors?

Other companies in Protagonist Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Avidity Biosciences (NASDAQ:RNA), Ultragenyx Pharmaceutical (NASDAQ:RARE), MoonLake (NASDAQ:MLTX) and Ascentage Pharma Group (NASDAQ:AAPG).

What is the forecast, or price target, for Protagonist Therapeutics (PTGX) stock?

Protagonist Therapeutics has a consensus price target of $60.27.

What is the current price for Protagonist Therapeutics (PTGX)?

The stock price for Protagonist Therapeutics (NASDAQ: PTGX) is $44.41 last updated May 15, 2025 at 4:00 PM EDT.

Does Protagonist Therapeutics (PTGX) pay a dividend?

There are no upcoming dividends for Protagonist Therapeutics.

When is Protagonist Therapeutics (NASDAQ:PTGX) reporting earnings?

Protagonist Therapeutics’s Q2 earnings are confirmed for Tuesday, August 5, 2025.

Is Protagonist Therapeutics (PTGX) going to split?

There is no upcoming split for Protagonist Therapeutics.

What sector and industry does Protagonist Therapeutics (PTGX) operate in?

Protagonist Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.